Form 8-K APPLIED DNA SCIENCES For: Dec 06

December 6, 2016 4:06 PM

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

  

 

 

Date of Report (Date of earliest event reported): December 6, 2016

  

Applied DNA Sciences, Inc.

(Exact name of registrant as specified in its charter)

  

Delaware

(State or other jurisdiction
of incorporation)

001-36745

(Commission File Number)

59-2262718

(IRS Employer

Identification No.)

 

50 Health Sciences Drive

Stony Brook, New York 11790

(Address of principal executive offices; zip code)

  

Registrant’s telephone number, including area code:  

631-240-8800

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 2.02  Results of Operations and Financial Condition.

 

On December 6, 2016, Applied DNA Sciences, Inc. (“Applied DNA Sciences” or the “Company”) issued a press release announcing its results of operations for the fiscal quarter and fiscal year ended September 30, 2016. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01.   Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1 Press Release of Applied DNA Sciences, Inc. dated December 6, 2016 regarding results of operations for the fiscal quarter and fiscal year ended September 30, 2016.

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 6, 2016 APPLIED DNA SCIENCES, INC.
   
By: /s/ James A. Hayward
Name: James A. Hayward
Title: Chief Executive Officer

 

 

 

EXHIBIT INDEX

  

Exhibit No. Description
99.1 Press Release issued by Applied DNA Sciences, Inc. dated December 6, 2016 regarding results of operations for the fiscal quarter and fiscal year ended September 30, 2016.

 

 

 

 

 

 

 

Exhibit 99.1

 

 

Applied DNA Sciences Reports

Fiscal Fourth Quarter and Year End Results

 

Company To Hold Conference Call and Webcast Today,

Tuesday, December 6, 2016 at 4:30 PM EST.

DRAFT

 

STONY BROOK, N.Y. - December 6, 2016 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a provider of DNA-based supply-chain, anti-counterfeiting and anti-theft technology, product genotyping and product authentication solutions, announced financial results for the full fiscal year and quarter ended September 30, 2016.

 

Commenting on Applied DNA’s performance for the fiscal year, Dr. James A. Hayward, president and chief executive officer, stated, “Fiscal 2016 stands out for the growing maturation of three key verticals – textiles, government/defense and pharmaceuticals – reflecting our efforts to build demand combined with favorable industry developments. Our financial results for the year, however, do not yet reflect these efforts. Revenues were negatively impacted by excess 2015 customer inventory cotton taggant that curtailed orders in fiscal 2016 despite an expected multiple in total usage of marked cotton tagged in the 2015 and 2016 ginning seasons, and by the completion of two non-recurring government contracts. Our pharmaceutical efforts significantly increased at the end of Q3, too soon to see results in fiscal 2016."

 

Fiscal Fourth Quarter Results:

·Revenues decreased 59% for the fourth quarter of fiscal 2016 to $1.6 million, compared with $4.0 million reported in the fourth quarter of fiscal 2015, and increased 151% from the $653 thousand reported in the third fiscal quarter ended June 30, 2016. The year-over-year decrease in revenues resulted primarily from decreased sales to the textile industry for the securing of global cotton supply chains and reduced revenues from two non-recurring government commercialization contract awards that were completed in the fourth quarter of fiscal 2016. The increase in revenues for the fourth quarter of fiscal 2016 as compared to the prior fiscal quarter is primarily a result of shipments of DNA concentrate to mark cotton.
·Total operating expenses were $3.6 million, compared with $4.2 million in the prior fiscal year’s quarter, a decrease of approximately $609 thousand or 14%. The decrease in year-over-year total operating expenses is primarily attributable to a decrease in SG&A expense of approximately $463 thousand and a decrease in research and development expense of approximately $158 thousand.
·Net loss for the quarter ended September 30, 2016 was $2.4 million, or $0.10 per share, compared with a net loss of $496 thousand, or $0.02 per share, for the quarter ended September 30, 2015 and a net loss of $3.4 million, or $0.14 per share, for the quarter ended June 30, 2016.
·Excluding non-cash expenses, Adjusted EBITDA for the quarter ended September 30, 2016 was negative $1.7 million compared to a positive Adjusted EBITDA of $213 thousand for the same quarter last year and a negative Adjusted EBITDA of $2.6 million in the prior fiscal quarter. See below for information regarding non-GAAP measures.

 

Fiscal 2016 Financial Results:

 

·The Company reported fiscal 2016 revenues of $4.2 million, a decrease of 54%, as compared to $9.0 million in the prior fiscal year. The decrease in year-over-year total revenues is primarily attributable to decreases in revenue of approximately $2.7 million in the textile industry for protecting cotton supply chains, and two government contract awards of approximately $1.8 million, which expired in July and August 2016.
·Total operating expenses were $15.6 million, compared with $16.5 million in the prior year, a decrease of approximately $839 thousand or 5%. The decrease is primarily attributable to a decrease in stock based compensation expense of $2.1 million, associated with grants to employees that vested immediately during fiscal 2015 whereas the grants to employees during fiscal 2016 have a four year vesting period, as well as stock based compensation expense associated with stock option modifications resulting from the extension of certain stock options, and to a lesser extent, the acceleration of vesting terms, offset by an increase in R&D of $1.1 million primarily attributable to development costs incurred in relation to the two government development contract awards as well as costs related to the cooperative research and development agreement with the USDA for enhanced cotton genotyping.

 

   

 

  

·Net loss for fiscal 2016 was $12.2 million, or $0.51 per share, compared with a net loss of $11.9 million, or $ 0.63 per share, in the prior year.
·Excluding non-cash expenses, Adjusted EBITDA for fiscal 2016 was negative $9.2 million, as compared to a negative Adjusted EBITDA of $3.2 million in the prior year. See below for information regarding non-GAAP measures.

 

Dr. Hayward added “In textiles, major brands and retailers are responding to the value proposition of our technology to secure and purify the global cotton supply chain, and demand for DNA-tagged cotton is now coming from a broader set of supply chain participants. We believe recent reports of mislabeled Egyptian cotton goods will further catalyze demand given that similar mislabeling occurs in goods manufactured from premium US Pima cotton. In our government/military vertical, the completion of the RIF and SBIR development contracts has yielded a marking platform that can mark at high volumes at the point of manufacture of multiple commodities. This platform gives us entrée into commercial OEMs for the marking of commodities applicable to defense, industrial and consumer markets. Our go-to-market strategy includes channel partners, such as Action-Pak a contract packaging services provider with a broad base of military, industrial and commercial suppliers, to further our penetration of these markets and educate OEMs on our validation and authentication solutions to meet their supply chain security needs.”

 

Operational Highlights:

 

·On November 22, the Company announced a technology partnership with ITL Group to utilize its SigNature DNA forensic marking system to support global apparel and footwear brands and retailers in their ongoing battle against product counterfeiters.
·On November 17, the Company announced a reseller agreement with Action-Pak, a contract packaging services provider for military and commercial supply chains identified in trials during the Rapid Innovation Fund Contract from the Office of the Secretary of Defense that will enable it to further penetrate military and commercial markets with its DNA-based products.
·On November 15, the Company announced a one-year firm fixed price Indefinite Delivery Purchase Order from the U.S. Defense Logistics Agency (DLA) for the marking of FSC 5962 microcircuits. This new order continues the marking of FSC 5962 first awarded to Applied DNA by DLA in December 2014, and is now implemented via a low-throughput, high variability marking system developed under a Rapid Innovation Fund contract with the Office of the Secretary of Defense.
·On November 10, Applied DNA reported that it anticipated total market usage of cotton tagged in the 2016 ginning season to be approximately 150 million pounds, of which the Company shipped orders for its SigNature T DNA concentrate to tag 93 million pounds.
·On November 7, the Company closed a private placement with a healthcare-dedicated institutional investor to purchase $5 million of common stock and warrants, before deducting the placement agent's fee and other estimated offering expenses, at a combined price of $2.20 per share of common stock and warrant. The company intends to use the proceeds for general corporate purposes, including working capital, capital expenditures, business development and research and development.
·On October 14, the Company announced the appointment of Robert B. Catell, former Chairman and Chief Executive Officer of KeySpan Corporation, past Chairman of the Board of Directors of the United States Energy Association and Chairman of the American Gas Association, to its Board of Directors. As an accomplished global energy industry leader, Mr. Catell is assisting with Applied DNA’s penetration of the market for critical infrastructure protection.
·On October 11, the Company announced the launch of its new DNA Transfer System at cotton gins in Arkansas, California and Texas. The system is designed to handle greater volumes of SigNature T tagging than the prior generation System and is equipped with real-time monitoring, security and data capture to ensure efficient and consistent DNA tagging of cotton fibers during ginning.
·On September 14, Applied DNA Sciences introduced its SigNature® DNA Molecular Taggant to pharmaceutical supply chain experts, regulators and leaders from the pharmaceutical industry. Molecular taggants can be deployed on pharmaceutical inks used on tablets and capsules or on the coating on tablets that ensures a mark of authenticity for regulatory inspectors and patients alike. Applied DNA’s SigNature DNA Molecular Taggants satisfy the principles established by FDA Guidelines for inclusion in pharmaceuticals.

 

   

 

  

Concluded Dr. Hayward, “As we look ahead to fiscal 2017, growing market adoption by participants in our textile, government/defense and pharmaceutical verticals are expected to give us a foundation for revenue growth with opportunities in diagnostics and asset-marking, among others, contributing incremental revenue. We remain focused on tight control of operating expenses and have the financial resources to pursue our growth initiatives.”

 

Fiscal Fourth Quarter 2016 Conference Call Information

 

The Company will hold a conference call and webcast to discuss its fiscal fourth quarter and year-end 2016 results on Tuesday, December 6, 2016 at 4:30 PM EST. To participate on the conference call, please follow the instructions below. While every attempt will be made to answer investors’ questions on the Q&A portion of the call, due to the large number of expected participants, not all questions may be answered.

 

To Participate:

 

·Participant Toll Free:1-844-887-9402
·Participant Toll: 1-412-317-6798
·Please ask to be joined to the Applied DNA Sciences call

 

Live webcast: https://services.choruscall.com/links/apdn161206.html

 

Replay (available 1 hour following the conclusion of the live call):

 

·Participant Toll Free: 1-877-344-7529
·Participant Toll: 1-412-317-0088
·Participant Passcode: 10096403
·Webcast replay: https://services.choruscall.com/links/apdn161206.html

 

For those investors unable to attend the live call, a copy of the presentation is expected to be posted by end of business on December 6, 2016 and available under the ‘Presentations’ section of the company’s Investor Relations web site: http://adnas.com/adnas_home/investors/.

 

Information about Non-GAAP Financial Measures

 

As used herein, “GAAP” refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company’s historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP. We use this non-GAAP financial measure for internal financial and operational decision making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

 

“EBITDA”- is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.

 

“Adjusted EBITDA”- is defined as EBITDA adjusted to exclude (i) change in fair value of warrant liability, (ii) the loss on conversion of promissory notes, (iii) stock-based compensation and (iv) other non-cash expenses.

 

   

 

  

About Applied DNA Sciences

 

 

We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. Our patented DNA-based solutions can be used to identify, tag, track, and trace products, to help assure authenticity, traceability and quality of products. SigNature® DNA describes the platform ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. We are also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

 

Go to adnas.com for more information, events and to learn more about how Applied DNA Sciences makes life real and safe. Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW. 

 

Forward-Looking Statements

 

The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, which is available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

 

 

 

Investor contact: Debbie Bailey, 631-240-8817, debbie.bailey@adnas.com

 Sanjay M. Hurry, 212-838-3777, LHA, shurry@lhai.com

Media contact: Susan Forman, Dian Griesel Int’l., 212-825-3210, sforman@dgicomm.com 

Web: www.adnas.com 

Twitter: @APDN

 

Financial Tables Follow

 

   

 

 

APPLIED DNA SCIENCES, INC.

CONSOLIDATED BALANCE SHEETS

 

   September 30, 
   2016   2015 
ASSETS          
Current assets:          
Cash and cash equivalents  $4,479,274   $7,312,184 
Accounts receivable, net of allowance of $32,965 and $7,140 at September 30, 2016 and 2015, respectively   6,374,895    3,929,517 
Inventories   297,759    - 
Prepaid expenses and other current assets   200,006    293,351 
Total current assets   11,351,934    11,535,052 
           
Property, plant and equipment-net of accumulated depreciation of $1,263,200 and $852,867 at September 30, 2016 and 2015, respectively   792,499    572,107 
           
Other assets:          
Long term accounts receivables   1,535,000    1,500,000 
Deposits   61,126    62,988 
Deferred offering costs   13,986    - 
Goodwill   285,386    285,386 
Intangible assets, net of accumulated amortization of $423,649 and $238,368, as of September 30, 2016 and 2015, respectively   1,525,900    1,598,779 
           
Total Assets  $15,565,831   $15,554,312 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current liabilities:          
Accounts payable and accrued liabilities  $2,247,341   $2,385,006 
Deferred revenue   1,837,588    282,050 
Total current liabilities   4,084,929    2,667,056 
           
Long term accounts payable   215,500    320,400 
Long term deferred revenue   900,000    - 
           
Total liabilities   5,200,429    2,987,456 
           
Commitments and contingencies          
           
Stockholders’ Equity          
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2016 and 2015   -    - 
Series A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of September 30, 2016 and 2015   -    - 
Series B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of September 30, 2016 and 2015   -    - 
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 24,078,756 and 21,504,578 shares issued and outstanding as of September 30, 2016 and 2015, respectively   24,079    21,505 
Additional paid in capital   234,158,711    224,186,760 
Accumulated deficit   (223,817,388)   (211,641,409)
Total stockholders’ equity   10,365,402    12,566,856 
           
Total Liabilities and Stockholders’ Equity  $15,565,831   $15,554,312 

 

   

 

  

APPLIED DNA SCIENCES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   Three Months Ended September 30,   Twelve Months Ended September 30, 
   2016   2015   2016   2015 
Revenues:                    
                     
Product revenues  $1,381,168   $3,018,690   $2,538,202   $5,435,776 
                     
Service revenues   254,927    961,575    1,648,225    3,572,723 
Total revenues   1,636,095    3,980,265    4,186,427    9,008,499 
Cost of revenues   441,971    255,254    746,582    384,269 
                     
Operating expenses:                    
Selling, general and administrative   2,623,151    3,086,448    11,239,397    13,410,256 
Research and development   832,227    989,981    3,693,810    2,577,307 
Depreciation and amortization   148,528    136,496    706,496    490,641 
                     
Total operating expenses   3,603,906    4,212,925    15,639,703    16,478,204 
                     
LOSS FROM OPERATIONS   (2,409,782)   (487,914)   (12,199,858)   (7,853,974)
                     
Other income (expense):                    
Interest income (expense), net   1,437    3,340    11,004    (23,468)
Other (expense) income, net   (6,731)   (11,460)   12,875    (28,313)
Loss on conversion of promissory notes   -    -    -    (980,842)
Loss on change in fair value of warrant liability   -    -    -    (2,994,540)
                     
Net loss before provision for income taxes   (2,415,076)   (496,034)   (12,175,979)   (11,881,137)
                     
Provision for income taxes   -    -    -    - 
                     
NET LOSS  $(2,415,076)  $(496,034)  $(12,175,979)  $(11,881,137)
                     
Net loss per share-basic and diluted  $(0.10)  $(0.02)  $(0.51)  $(0.63)
                     
Weighted average shares outstanding-  Basic and diluted   24,078,657    21,483,946    23,693,096    18,938,283 

 

   

 

  

APPLIED DNA SCIENCES, INC.

CALCULATION AND RECONCILIATION OF ADJUSTED EBITDA

 

   Three Months Ended September 30,   Twelve Months Ended September 30, 
   2016   2015   2016   2015 
                 
Net Loss  $(2,415,076)  $(496,034)  $(12,175,979)  $(11,881,137)
                     
Interest (income) expense, net   (1,437)   (3,340)   (11,004)   23,468 
Depreciation and amortization   148,528    136,496    706,496    490,641 
Loss on change in fair value of warrant liability               2,994,540 
Stock based compensation expense   594,656    562,933    2,116,960    4,158,564 
Loss on conversion of promissory notes               980,842 
Bad debt expense   10,577    13,246    116,824    34,996 
                     
Total non-cash items   752,324    709,335    2,929,276    8,683,051 
                     
Consolidated Adjusted EBITDA (loss)   (1,662,752)   213,301    (9,246,703)   (3,198,086)

 

   

Categories

SEC Filings

Next Articles